GlassScriptPhysician profile
John M Goldenring
NPI 1063521961
$89,722.33
in general payments reported to CMS, 2019-2025
16 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $4,865 · 2021: $9,291 · 2022: $8,990 · 2023: $18K · 2024: $1,800 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $6,531 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,462.50 |
| Travel and Lodging | $6,530.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Food and Beverage | $1,182.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $16,212.57 | 2019-2025 | |
| Genentech USA, INC. | $12,879.72 | 2021-2025 | Xolair |
| Genentech, INC. | $9,451.17 | 2019 | |
| Kite Pharma, INC. | $7,555.26 | 2019-2022 | |
| Novo Nordisk As | $7,400.00 | 2020-2022 | |
| Genmab U.S., INC. | $6,585.17 | 2023 | Epkinly |
| Novartis Pharmaceuticals Corporation | $5,053.07 | 2019 | |
| Biomarin Pharmaceutical INC. | $4,887.13 | 2019 | |
| Daiichi Sankyo INC. | $4,850.74 | 2021 | |
| Baxter Healthcare | $4,400.00 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,382.50 | 2023 | Entyvio |
| Emd Serono, INC. | $2,565.00 | 2020 | |
| Pulmonx Corporation | $2,000.00 | 2022 | |
| Coloplast Corp | $1,800.00 | 2024 | |
| Alnylam Pharmaceuticals INC. | $400.00 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $300.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Goldenring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.